Skip to main content
. 2021 Aug 4;157(9):1047–1055. doi: 10.1001/jamadermatol.2021.3023

Figure 2. Efficacy Over Time.

Figure 2.

A, Proportion of patients achieving 75% improvement in Eczema Area and Severity Index (EASI75) B, Proportion of patients achieving 90% improvement in EASI (EASI90). C Proportion of patients achieving 100% improvement in EASI (EASI100). D, Mean percentage change in Worst Pruritus Numerical Rating Scale (NRS) for patients treated with upadacitinib or dupilumab by nonresponder imputation incorporating multiple imputation to handle missing data due to COVID-19. Error bars indicate 95% CIs (synthetic result based on t test distribution from the PROC MIANALYZE procedure in SAS if there were missing data due to COVID-19 or was based on the normal approximation to the binomial distribution if there were no missing data due to COVID-19).

aP ≤ .001.

bP ≤ .01.

cP ≤ .05.